USJ Stock Overview Develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. More details
Rewards Risk Analysis No risks detected for USJ from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
USANA Health Sciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for USANA Health Sciences Historical stock prices Current Share Price US$34.80 52 Week High US$48.20 52 Week Low US$31.40 Beta 0.89 1 Month Change -3.33% 3 Month Change 10.13% 1 Year Change -24.02% 3 Year Change -60.68% 5 Year Change -52.33% Change since IPO 111.17%
Recent News & Updates
USANA Health Sciences, Inc. (NYSE:USNA) acquired 78.85% stake in Hiya Health Products LLC for approximately $260 million. Dec 25 USANA Health Sciences, Inc. (NYSE:USNA) acquired 78.85% stake in Hiya Health Products LLC for approximately $260 million. Dec 24
Third quarter 2024 earnings released: EPS: US$0.56 (vs US$0.59 in 3Q 2023) Oct 23
USANA Health Sciences, Inc. Updates Consolidated Earnings Guidance for the Fiscal Year 2024 Oct 23
USANA Health Sciences, Inc. to Report Q3, 2024 Results on Oct 22, 2024 Oct 08
USANA Health Sciences, Inc. Launches New, Innovative Skincare and Protein Products Resurfacing Serum and Whey Protein Isolate Up the Game for USANA Aug 19 See more updates
USANA Health Sciences, Inc. (NYSE:USNA) acquired 78.85% stake in Hiya Health Products LLC for approximately $260 million. Dec 25 USANA Health Sciences, Inc. (NYSE:USNA) acquired 78.85% stake in Hiya Health Products LLC for approximately $260 million. Dec 24
Third quarter 2024 earnings released: EPS: US$0.56 (vs US$0.59 in 3Q 2023) Oct 23
USANA Health Sciences, Inc. Updates Consolidated Earnings Guidance for the Fiscal Year 2024 Oct 23
USANA Health Sciences, Inc. to Report Q3, 2024 Results on Oct 22, 2024 Oct 08
USANA Health Sciences, Inc. Launches New, Innovative Skincare and Protein Products Resurfacing Serum and Whey Protein Isolate Up the Game for USANA Aug 19
Chief People Officer recently sold €220k worth of stock Aug 15
New major risk - Revenue and earnings growth Jul 25
Now 22% undervalued Jul 25
Second quarter 2024 earnings released: EPS: US$0.55 (vs US$0.90 in 2Q 2023) Jul 24
USANA Health Sciences, Inc. to Report Q2, 2024 Results on Jul 23, 2024 Jul 10
Founder & Chairman Emeritus recently sold €166k worth of stock Jun 13
Chief People Officer recently sold €122k worth of stock May 24
Chief Financial Officer recently sold €216k worth of stock May 08
Insider recently sold €167k worth of stock May 03
First quarter 2024 earnings released: EPS: US$0.86 (vs US$0.95 in 1Q 2023) May 01
USANA Health Sciences, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 11
USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024 Mar 23
Chief Legal Officer recently sold €215k worth of stock Mar 05
Full year 2023 earnings released: EPS: US$3.31 (vs US$3.60 in FY 2022) Feb 29
New major risk - Revenue and earnings growth Feb 09
New major risk - Revenue and earnings growth Feb 07
Full year 2023 earnings released: EPS: US$3.30 (vs US$3.60 in FY 2022) Feb 07
USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Feb 07
USANA Health Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024 Jan 17
Investor sentiment deteriorates as stock falls 17% Oct 31
USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023 Oct 25
Third quarter 2023 earnings released: EPS: US$0.59 (vs US$0.78 in 3Q 2022) Oct 25
USANA Health Sciences, Inc. to Report Q3, 2023 Results on Oct 24, 2023 Oct 10
Now 20% undervalued after recent price drop Sep 06
Now 21% undervalued after recent price drop Aug 22
Chief People Officer recently sold €217k worth of stock Aug 01
USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023 Jul 26
Second quarter 2023 earnings released: EPS: US$0.89 (vs US$1.00 in 2Q 2022) Jul 26
USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023 Jul 12
USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023 Jul 11
Insufficient new directors Jun 01
Insider recently sold €736k worth of stock May 10
Independent Director recently sold €149k worth of stock Apr 29
First quarter 2023 earnings released: EPS: US$0.95 (vs US$1.16 in 1Q 2022) Apr 26
Chairman of the Board & CEO recently sold €301k worth of stock Mar 16 Kevin Guest to Transit to the Role of Executive Chairman of USANA Health Sciences, Inc., Effective July 1, 2023
Insider recently sold €108k worth of stock Feb 12
Full year 2022 earnings released: EPS: US$3.59 (vs US$5.78 in FY 2021) Feb 08
Usana Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2023 Feb 08 USANA Health Sciences, Inc. to Report Q4, 2022 Results on Feb 07, 2023
Insider recently sold €76k worth of stock Dec 07
USANA Health Sciences, Inc. (NYSE:USNA) acquired Rise Bar and Oola Global, LLC. Nov 30
Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.37 in 3Q 2021) Oct 27
USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Year 2022 Oct 27
USANA Health Sciences, Inc. to Report Q3, 2022 Results on Oct 25, 2022 Oct 11
Chief People Officer recently sold €346k worth of stock Aug 18
Chief Financial Officer recently sold €75k worth of stock Aug 03
USANA Health Sciences, Inc. Announces Rejoining of J. Scott Nixon to Board of Directors Jul 28
USANA Health Sciences, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022 Jul 27
Second quarter 2022 earnings released: EPS: US$1.00 (vs US$1.89 in 2Q 2021) Jul 27 USANA Health Sciences, Inc. to Report Q2, 2022 Results on Jul 26, 2022
Insider recently sold €95k worth of stock Jun 18
First quarter 2022 earnings released: EPS: US$1.15 (vs US$1.47 in 1Q 2021) Apr 29
USANA Health Sciences, Inc. Revises Earnings Guidance for Fiscal Year 2022 Apr 27
USANA Health Sciences, Inc. to Report Q1, 2022 Results on Apr 26, 2022 Apr 05
USANA Health Sciences, Inc., Annual General Meeting, May 09, 2022 Mar 31
Chief Legal Officer recently sold €268k worth of stock Mar 05
Chief Operating Officer recently sold €214k worth of stock Feb 17
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 09
USANA Health Sciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022 Feb 09
Chief Sales Officer recently sold €79k worth of stock Dec 10
Chief Sales Officer recently sold €110k worth of stock Nov 05
Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.45 in 3Q 2020) Oct 27 USANA Health Sciences, Inc. Provides Earnings Guidance for the Third Quarter of 2021
Independent Director recently sold €51k worth of stock Jul 31
Second quarter 2021 earnings released: EPS US$1.87 (vs US$1.33 in 2Q 2020) Jul 29
Director recently sold €51k worth of stock Jun 22
USANA Launches New Product Line Jun 16
Independent Director has left the company May 14
First quarter 2021 earnings released: EPS US$1.45 (vs US$1.24 in 1Q 2020) Apr 29
USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year 2021 Apr 29
New 90-day high: €83.00 Mar 05
Full year 2020 earnings released: EPS US$5.89 (vs US$4.44 in FY 2019) Mar 05
Revenue beats expectations Mar 05
Insider recently sold €413k worth of stock Feb 18
USANA Announces Formation of Board Sustainability Committee Feb 17
Full year 2020 earnings released: EPS US$5.87 (vs US$4.44 in FY 2019) Feb 12
Revenue beats expectations Feb 12
New 90-day high: €80.00 Feb 11
New 90-day high: €70.50 Jan 26
USANA Health Sciences, Inc. to Report Q4, 2020 Results on Feb 09, 2021 Jan 07
New 90-day low: €62.00 Nov 18
Revenue beats expectations Nov 05 Shareholder Returns USJ DE Personal Products DE Market 7D 3.0% -0.001% 0.7% 1Y -24.0% -6.6% 8.4%
See full shareholder returns
Return vs Market: USJ underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is USJ's price volatile compared to industry and market? USJ volatility USJ Average Weekly Movement 5.4% Personal Products Industry Average Movement 3.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: USJ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: USJ's weekly volatility (5%) has been stable over the past year.
About the Company USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups.
Show more USANA Health Sciences, Inc. Fundamentals Summary How do USANA Health Sciences's earnings and revenue compare to its market cap? USJ fundamental statistics Market cap €675.34m Earnings (TTM ) €52.91m Revenue (TTM ) €839.30m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) USJ income statement (TTM ) Revenue US$861.97m Cost of Revenue US$164.98m Gross Profit US$697.00m Other Expenses US$642.65m Earnings US$54.34m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 10:24 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/28 Annual Earnings 2023/12/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources USANA Health Sciences, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Amy Vinson Avondale Partners Scott Van Winkle Canaccord Genuity Song Xue D.A. Davidson & Co.
Show 7 more analysts 
